Global Colorectal Cancer Awareness Report Reveals Lack of Symptoms Holding Hungarians Back from Screening

To uncover attitudes and the biggest challenges facing colorectal cancer (CRC) awareness and screening, BGI Genomics released its State of Colorectal Cancer Awareness Report, marking the first-ever global survey report on the world’s third most common cancer. This report seeks to motivate action to tackle the health challenges of today and tomorrow.                                            

This inaugural report seeks to better understand the global state of CRC awareness, as well as attitudes and actions towards CRC screening for average risk groups and CRC screening for hereditary genetic risk groups. 1,817 respondents from six countries and regions were surveyed: the U.K, Hungary, Saudi Arabia, Thailand, the Chinese mainland and Hong Kong.

Hungary had the highest global incidence rate of colorectal cancer, with 9,793 cases in 2020 based on World Cancer Research Fund data. CRC screening participation rate is very low in Hungary. Worryingly, this report finds Hungary tops the world (52.8%) in terms of lack of symptoms holding them back from screening, far above the global average of 37.0%.   

Despite 51.5% reporting that there is insufficient information about CRC and 34.5% citing costs holding them back from CRC screening, the report reveals several optimistic findings. For example, 88.8% are more willing to go for screening upon learning about the 5-year survival rate of 90% for early CRC detection.

​​​​​​​

Image Credit: BGI Genomics

Image Credit: BGI Genomics

“Early CRC detection offers the best outcome for individuals and healthcare policy. The treatment cost of late-stage CRC is sometimes more than ten times higher relative to early-stage CRC but with far lower survival rates,” said Yantao Li, PhD, BGI Genomics Director of Colorectal Cancer Screening Programme, South-East Asia. “That’s why more countries or regions are promoting early screening programs. For example, the European Commission is ramping up CRC screening programs.”

Other key takeaways from the report include:

Colonoscopy is the best-known screening test, but there is scope to enhance the awareness of other tests such as fecal tests. Though colonoscopy (68.2%) is the best-known screening test, it is more expensive and cumbersome relative to fecal testing which is lesser known at 49.5%. To promote this more affordable and flexible option, fecal testing awareness needs to be enhanced.

Doctors are the biggest factor for respondents to go for screening in the absence of symptoms. 62.5% will heed their doctor’s advice to undergo CRC screening. Therefore, it is vital that doctors are made more aware of CRC symptoms, ask the right questions to identify potential hereditary genetic risk and offer patients a range of screening options, to fit different lifestyles and budgets. In our opinion, the best colorectal cancer screening test is the one a patient will do.

Respondents are split when asked about bringing their family members for screening. 55.7% are aware that a family history of CRC increases their risk. According to the National Comprehensive Cancer Network (NCCN) guidelines, these family members should start screening at age 40 or 10 years before the earliest diagnosis of CRC in the family. The good news is that 67.2% who had CRC or a family history of CRC have taken their family members for screening. Conversely, only 31.2% of all respondents have taken their family members for CRC screening.

To read and view country or region-level comparisons, please see link to access the full BGI Genomics State of Colorectal Cancer Awareness Report 2023.

About BGI Genomics and COLOTECT          

BGI Genomics, headquartered in Shenzhen China, is the world’s leading integrated solutions provider of precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

​​​​​​​

Image Credit: BGI Genomics

COLOTECT is a non-invasive fecal DNA test developed by BGI Genomics for detecting CRC and precancerous lesions. It uses multiplex methylation-specific PCR (MSP) technology to trace abnormal DNA-methylation biomarkers in CRC from stool samples. It has 88% CRC sensitivity, and for early detection, its sensitivity for advanced adenoma is 46%, which are both superior to conventional fecal tests.